If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


_____ Brought to you by Wyatt Technology _____

Using SEC-MALS-IV to Characterize PLGA for FDA Generic Drug Approval



  November 14, 2019

  8:00 a.m. PST, 11:00 a.m. EST, 16:00 GMT, 17:00 CET




Traditionally, size exclusion chromatography (SEC) with column calibration is used to obtain the molar mass distributions of polymers such as PLGA. However, this technique has significant drawbacks as it assumes the standards used for calibration are physically similar to the sample, of particular concern for copolymers and other non-standard macromolecules. In comparison, multi-angle light scattering utilizes first principles to obtain a truly accurate molar mass measurement. Combined with a differential viscometer to measure intrinsic viscosity (IV), SEC-MALS produces a bevy of useful information from PLGA analysis, including branching ratio and conformation.

Generic drug manufacturers must prove that the excipients in their formulations are the same as the excipients in the reference drug. SEC-MAL-IV is the ideal technique for this purpose due to its robust and comprehensive nature. In this webinar, we will discuss the theory and technology of SEC-MALS-IV, and the parameters it quantifies. Additionally, we will discuss the utility of SEC-MALS-IV in satisfying FDA regulations for production of generic drug formulations.

Brought to you by:


Key Learning Objectives

  • Overview of SEC-MALS-IV and instrumentation used in the technique
  • The key parameters obtained from SEC-MALS-IV characterization of PLGA
  • How to compare PLGA derived from a commercial drug to a PLGA standard

Who Should Attend

  • Staff scientists involved in the characterization of PLGA and other polymeric excipients.
  • Pharmaceutical product managers developing generic drugs that contain polymers such as PLGA.


Chris Deng, Ph.D.
Application Scientist,
Wyatt Technology


Alexandra Taylor
Assistant Editor,